FDA approves Tregzi as the first precision-engineered regulatory T-cell immunotherapy.
The treatment is indicated for adult patients with high-risk blood cancers undergoing allo-HSCT.
PRECISION-T trial showed 78% of patients achieved one-year chronic GVHD-free survival.
Tregzi features a wholesale acquisition cost of $428,000 per treatment course.